Headed by Gordon Mills and Rehan Akbanie, the MD Anderson GCC will use reverse phase protein arrays to investigate tumor tissue from a variety of NCI projects.
The effort will use Biognosys' HRM method and is part of a move at Biodesix to add a "hypothesis-based approach" to its biomarker work, a company official said.
The funds will support a multi-center clinical study investigating the test's usefulness in diagnosing elderly patients with lower respiratory tract infections.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
In Science this week: caution urged in use of gene drives, and more.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."